Sequential Management with Gonadotropin-Releasing Hormone Agonist and Dienogest of Endometriosis-Associated Uterine Myoma and Adenomyosis

Abstract

Condition tags

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (24)

• A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis via openalex
• A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women via openalex
• A rare case of de novo gigantic ovarian abscess within an endometrioma via openalex
• Coexistence of endometriosis in women with symptomatic leiomyomas via openalex
• Dienogest: a new therapeutic agent for the treatment of endometriosis via openalex
• Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex
• Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial via openalex
• Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
• Endometrioma complicated by tubo-ovarian abscess in a woman with bacterial vaginosis via openalex
• High-dose pilot study with the novel progestogen dienogestin patients with endometriosis via openalex
• New progestagens for contraceptive use via openalex
• W2154693051 via openalex
• W2162130706 via openalex
• W4233426577 via openalex
• W1658784312 via openalex
• W1964793478 via openalex
• W1972292493 via openalex
• W2013397751 via openalex
• W2023365171 via openalex
• W2041524060 via openalex
• W2045458073 via openalex
• W2073744849 via openalex
• W2101417341 via openalex
• W2129134761 via openalex

Cited by (1)

• Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study 2015

Source provenance

openalex

last seen: 2026-06-10T17:14:06.276822+00:00